Vivo Bio Tech Limited (511509) fair value: what the stock is really worth
As of Oct 13, 2026: fair value of Vivo Bio Tech Limited ₹10.08, price ₹14.34, upside -29.7%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range ₹14.07 – ₹99.55 · fair‑value band ₹7.61 – ₹14.58 · the ₹14.34 price screens above the ₹10.08 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Vivo Bio Tech in your weekly email
Every Wednesday you see whether Vivo Bio Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vitro, in vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxico kinetic studies, genotoxicity screening, analytical services, etc.
Show more
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vitro, in vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxico kinetic studies, genotoxicity screening, analytical services, etc. It also supplies SPF lab animals. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Stock analysis
Vivo Bio Tech Limited (511509) currently trades at ₹14.34, while our model-based Fair Value estimate is ₹10.08, 29.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹37.52 per share, and 6 of the 6 models we run sit above the ₹14.34 price.
Bear case: the Earnings-Based group reads lowest at ₹15.50, and 0 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹7.61 (bear) to ₹14.58 (bull), the price of ₹14.34 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Vivo Bio Tech Limited reported revenue of ₹533M in FY2026 versus ₹514M in FY2022, a compound +0.9%/yr. Reported net income was −₹17.1M in FY2026.
Key figures
Market cap ₹639M (≈ $6.7M) · P/E ratio 12.2 · P/S ratio 1.25 · EPS (TTM) ₹3.27 · Net margin −3.2% · Return on assets (EBIT) 7.9% · Operating margin 12.5% · Revenue (TTM) ₹512M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −30%, 511509 screens richer than that median.
Fair Value models
Bear ₹7.61Fair Value ₹10.08Bull ₹14.58
Price ₹14.34 · Upside -29.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.76 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+14.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Start year 2021 (pandemic). Over 10 years: +6.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
23.3% (2021) → 20.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score20 · Bottom 25%
Fair Value upside−29.7% · Above median
Profitability
Return on assets4.8% · Top 25%
Net margin (TTM)8.2% · Above median
Operating margin (TTM)12.5% · Above median
Growth and dividend
Revenue growth−31.4% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.50× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)12.2× · Cheaper than median
P/B0.69× · Cheapest 25%
P/S (TTM)1.25× · Cheapest 25%
EV/EBITDA9.7× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)75· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vivo Bio Tech Limited Fair Value". https://www.fairvalue-calculator.com/stock/511509
Frequently asked questions
Is Vivo Bio Tech Limited (511509) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of ₹10.08 versus a price of ₹14.34, about −30% upside (overvalued).
What is the fair value of 511509?
Our model-based fair value for Vivo Bio Tech Limited is ₹10.08 (as of Oct 4, 2026), built from audited fundamentals. The current price: ₹14.34.
What is the quality score of 511509?
Vivo Bio Tech Limited has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vivo Bio Tech Limited (511509)?
Our model-based price target is the fair value of ₹10.08 (as of Oct 4, 2026) from 6 valuation models. Cautious scenario ₹7.61, optimistic scenario ₹14.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Vivo Bio Tech Limited stock forecast for 2026?
Our models put fair value at ₹10.08, about −30% upside versus a price of ₹14.34 (overvalued). Cautious scenario ₹7.61, optimistic scenario ₹14.58. The calculation is refreshed regularly with new filings.
What is the revenue of Vivo Bio Tech Limited (511509)?
Vivo Bio Tech Limited reported trailing-twelve-month revenue of about ₹512M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Vivo Bio Tech Limited (511509)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vivo Bio Tech Limited it is ₹10.08 per share (as of Oct 4, 2026), against a price of ₹14.34. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Vivo Bio Tech Limited stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 511509 trades above its calculated fair value: price ₹14.34, fair value ₹10.08, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 511509?
No. The price is what the market pays today (₹14.34); the fair value is what the company's own numbers justify (₹10.08). For Vivo Bio Tech Limited the two are ₹4.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vivo Bio Tech Limited worth?
The market values Vivo Bio Tech Limited at about ₹639M (market capitalisation, as of Oct 4, 2026). Per share that is ₹14.34; our models calculate a fair value of ₹10.08 per share.
What do the bullish and bearish scenarios say about 511509?
Our models span a range for Vivo Bio Tech Limited: cautious scenario ₹7.61, base ₹10.08, optimistic ₹14.58 per share (as of Oct 4, 2026, price ₹14.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 511509?
Vivo Bio Tech Limited trades at a price-to-earnings ratio of 12.2 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹10.08 is built from several models across several years. Other multiples: P/B 0.7, P/S 1.2, EV/EBITDA 9.7.
How solid is the balance sheet of Vivo Bio Tech Limited (511509)?
Balance-sheet figures for Vivo Bio Tech Limited (as of Oct 4, 2026): debt of 0.50 per unit of equity. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is 511509 from its 52-week high?
Vivo Bio Tech Limited trades at ₹14.34, about 62% below its 52-week high of ₹37.52 and 2% above the low of ₹14.07 (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹10.08 is for.
Which stocks are comparable to Vivo Bio Tech Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vivo Bio Tech Limited stock attractive at the current price?
The data as of Oct 4, 2026: price ₹14.34, calculated fair value ₹10.08 (−30%), Quality Score 20/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 511509 calculated?
We run Vivo Bio Tech Limited through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹10.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vivo Bio Tech Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vivo Bio Tech Limited (511509)?
The closing price on Oct 13, 2026 was ₹14.34. Our model-based fair value is ₹10.08, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vivo Bio Tech Limited right now?
Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (₹7.61 to ₹14.58) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Vivo Bio Tech Limited
How large is the market capitalisation of Vivo Bio Tech Limited (511509)?
The market capitalisation of Vivo Bio Tech Limited is ₹639M (≈ $6.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vivo Bio Tech Limited (511509)?
The price-to-sales ratio of Vivo Bio Tech Limited is 1.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vivo Bio Tech Limited (511509)?
Earnings per share at Vivo Bio Tech Limited are ₹3.27 (price ÷ EPS = P/E 12.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vivo Bio Tech Limited (511509)?
The net margin of Vivo Bio Tech Limited is −3.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Vivo Bio Tech Limited (511509)?
On an EBIT basis the return on assets of Vivo Bio Tech Limited is 7.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vivo Bio Tech Limited (511509)?
The operating margin of Vivo Bio Tech Limited is 12.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vivo Bio Tech Limited (511509)?
Revenue at Vivo Bio Tech Limited is growing −31.4% versus a year earlier (3y avg +0.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vivo Bio Tech Limited (511509)?
Earnings per share at Vivo Bio Tech Limited are growing −19.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vivo Bio Tech Limited (511509) generate?
The free cash flow of Vivo Bio Tech Limited is −₹25.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vivo Bio Tech Limited (511509) carry?
The net debt of Vivo Bio Tech Limited is ₹659M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vivo Bio Tech Limited in the live analysis
One click puts Vivo Bio Tech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
